ABSTRACT
Skin diseases are complex and cannot be explained solely by genetic or environmental factors but are also significantly shaped by social influences. This review illuminates the bidirectional relationship between social factors and skin diseases, demonstrating how social determinants such as socioeconomic status, living environment, and psychosocial stress can influence the onset and progression of skin conditions. Simultaneously, it explores how skin diseases can affect individuals' social lives and work capability, leading to a cycle of social withdrawal and further deterioration of the condition. The paper describes the need for a holistic approach in dermatology that goes beyond the biomedical perspective and incorporates social factors to develop effective prevention and treatment strategies. The increasing prevalence of skin diseases in Europe and the expected rise in allergies due to climate change make the consideration of social determinants even more urgent. The findings of this review aim to raise awareness of the complex interconnections between social factors and skin health and contribute to reducing social disparities in skin health.
Subject(s)
Skin Diseases , Socioeconomic Factors , Humans , Skin Diseases/epidemiology , Skin Diseases/psychology , Skin Diseases/therapy , Social Determinants of Health , Social Factors , Risk Factors , Europe/epidemiology , Social Class , Stress, Psychological/epidemiologyABSTRACT
BACKGROUND: Massage therapists are particularly exposed to constituents of massage preparations, wet work and mechanical strain and therefore, at high risk to develop occupational dermatitis (OD). OBJECTIVES: To describe the sensitization spectrum of massage therapists with OD. PATIENTS AND METHODS: In a retrospective study, patch test data of patients with OD (128 massage therapists and 24 374 patients working in other professions) collected by the Network of Departments of Dermatology (IVDK, 2008-2020) were analysed. RESULTS: Hand dermatitis (91.4%) and allergic contact dermatitis (34.4%) were common in massage therapists with OD. Most frequent were sensitizations to fragrances/essential oils which were found in 54 (42.2%) massage therapists and thus, more often than in other patients with OD. Concomitant positivity to several fragrances/essential oils was frequent. In 8 (14.8%) of the 54 massage therapists, sensitizations to fragrances/essential oils were not detected with the baseline series, but only with special fragrance series. CONCLUSIONS: Allergic contact dermatitis is common in massage therapists with OD and is mainly caused by fragrances and essential oils. Hence, massage therapists should be aware of this risk. When OD is suspected, not only the baseline series, but also special fragrance series should be patch tested in this occupational group.
Subject(s)
Dermatitis, Allergic Contact , Dermatitis, Occupational , Dermatology , Oils, Volatile , Perfume , Humans , Patch Tests/adverse effects , Dermatitis, Occupational/diagnosis , Dermatitis, Occupational/epidemiology , Dermatitis, Occupational/etiology , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/epidemiology , Dermatitis, Allergic Contact/etiology , Retrospective Studies , Oils, Volatile/adverse effects , Information Services , Massage , AllergensABSTRACT
Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus at least once in the lifetime with a 12-month incidence of 7%. In patient populations its frequency is much higher depending on the underlying cause, ranging from around 25% in haemodialysis patients to 100% in skin diseases such as urticaria and atopic dermatitis (AD). Pruritus may be the result of a dermatological or non-dermatological disease. Especially in non-diseased skin it may be caused by systemic, neurological or psychiatric diseases, as well as being a side effect of medications. In a number of cases chronic pruritus may be of multifactorial origin. Pruritus needs a precise diagnostic work-up. Management of chronic pruritus comprises treatment of the underlying disease and topical treatment modalities, including symptomatic antipruritic treatment, ultraviolet phototherapy and systemic treatment. Treating chronic pruritus needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. We present the updated and consensus based (S2k) European guideline on chronic pruritus by a team of European pruritus experts from different disciplines. This version is an updated version of the guideline that was published in 2012 and updated in 2014 (www.euroderm.org).
Subject(s)
Dermatology/standards , Pruritus/therapy , Chronic Disease , Europe/epidemiology , Humans , Incidence , Predictive Value of Tests , Pruritus/diagnosis , Pruritus/epidemiology , Risk Factors , Treatment OutcomeABSTRACT
BACKGROUND: The CARPE registry was set up in 2009 to prospectively investigate the management of patients with chronic hand eczema (CHE). OBJECTIVES: To report comprehensive follow-up data from the CARPE registry. PATIENTS AND METHODS: We investigated sociodemographic and clinical characteristics, provision of medical care, physician-assessed outcomes, and patient-reported outcomes (PROs). Data were collected between 2009 and 2016, with up to 5 years of follow-up, and are reported descriptively. RESULTS: Overall, 1281 patients were included in the registry (53.7% female). Mean age was 47.0 years. Of the patients, 793 and 231 completed the 2-year follow-up and 5-year follow-up, respectively. At baseline, 5.4% had changed or given up their job because of CHE, the average duration of CHE was 6.1 years, and, in 22.4%, the CHE was severe according to physician global assessment. Systemic treatment (alitretinoin, acitretin, and methotrexate) was prescribed at least once to 39.0% of the patients during the course of the follow-up. Disease severity, quality of life and treatment satisfaction improved over time, and the proportion of patients receiving systemic treatments decreased. CONCLUSIONS: Under continued dermatological care, substantial improvements in disease severity and PROs over time was achieved during the course of the CARPE registry, even in patients with long-standing and severe hand eczema.
Subject(s)
Dermatitis, Allergic Contact/physiopathology , Hand Dermatoses/physiopathology , Registries , Acitretin/therapeutic use , Administration, Cutaneous , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Aged, 80 and over , Alitretinoin/therapeutic use , Chronic Disease , Dermatitis, Allergic Contact/etiology , Dermatitis, Allergic Contact/therapy , Dermatologic Agents/therapeutic use , Eczema/physiopathology , Female , Follow-Up Studies , Hand Dermatoses/therapy , Humans , Male , Methotrexate/therapeutic use , Middle Aged , Outcome Assessment, Health Care , PUVA Therapy , Patient Reported Outcome Measures , Ultraviolet Therapy , Urea/therapeutic use , Young AdultABSTRACT
The aim of the CARPE registry is to investigate characteristics and medical care in patients affected by chronic hand eczema. Patients are assessed by dermatological examination and patient questionnaire. Socio-economic and clinical data are collected, and quality of life is measured using the Dermatology Life Quality Index (DLQI). A total of 1,163 patients with chronic hand eczema were eligible for analysis (mean age 47.0 years; 54.6% female; mean disease duration 7.6 years). At inclusion, chronic hand eczema was very severe in 23.4%, severe in 47.0%, moderate in 20.1%, and clear or almost clear in 9.6% of patients. Median DLQI was 8.0. In all, 93.8% of patients reported use of topical corticosteroids, 25.6% systemic antihistamines, 28.3% topical calcineurin-inhibitors, 38.0% ultraviolet phototherapy, and 35.3% systemic treatment (19.7% alitretinoin) prior to inclusion in the registry. A significant proportion of patients may not receive adequate treatment according to the guideline on management of hand eczema.
Subject(s)
Eczema/complications , Eczema/therapy , Hand Dermatoses/complications , Hand Dermatoses/therapy , Administration, Topical , Adolescent , Adult , Aged , Aged, 80 and over , Alitretinoin , Calcineurin Inhibitors , Chronic Disease , Female , Germany , Glucocorticoids/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Male , Middle Aged , Occupations/statistics & numerical data , Pruritus/etiology , Quality of Life , Registries , Severity of Illness Index , Tretinoin/therapeutic use , Ultraviolet Therapy , Young AdultABSTRACT
During pregnancy and also during childhood, pruritus can have manifold aetiologies and should therefore always be taken seriously. In pregnancy, pruritus is the main dermatological symptom, occurring in 18% of women. Pregnancy-specific dermatological diseases such as polymorphic eruption of pregnancy (PEP), Pemphigoid (Herpes) gestationis, Pruritus gravidarum are accompanied by severe pruritus and scratching. In children, it mainly occurs along with dermatoses but in rare cases with systemic diseases such as renal or liver failure. Mostly, it appears in the setting of atopic dermatitis (AD). Both groups of patients require therapeutic regimens of their own. The use of topical and systemic treatments depends on the underlying aetiology of the pruritus and the stage and status of the skin. Because of potential effects on the fetus, the treatment of pruritus in pregnancy requires prudent consideration of whether the severity of the underlying disease warrants treatment and selection of the safest treatments available. Systemic treatments such as systemic glucocorticosteroids, a restricted number of antihistamines and ultraviolet phototherapy may be necessary in severe and generalized forms of pruritus in pregnancy. In children, the physician has to consider that topically applied drugs may cause intoxication due to the different body volume/body surface proportion. The dosages of systemic drugs need to be adapted in children and ultraviolet phototherapy should be performed with caution due to possible longterm photo damage of the skin. In a two center approach, we wanted to highlight the major aetiologies of pruritus during pregnancy and in children and point out the mainstays of antipruritic therapy in these two challenging groups of patients according to our clinical experiences. For the future, it would be desirable for all disciplines involved (dermatologist, gynaecologist, paediatrician, general practitioner) to cooperate closely to expand the clinical and scientific knowledge of pruritus in these groups of pruritus patients.
Subject(s)
Pregnancy Complications , Pruritus , Antipruritics/adverse effects , Antipruritics/therapeutic use , Child , Diagnosis, Differential , Female , Humans , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Complications/drug therapy , Pregnancy Complications/pathology , Pruritus/drug therapy , Pruritus/etiology , Pruritus/pathologyABSTRACT
As shown in previous experimental studies, topical capsaicin has a strong inhibitory effect in histamine-induced itch in healthy persons, but not in patients with atopic eczema. However, in serotonin-induced itch, it was not a sufficient antipruritic. Eleven pruritic patients on hemodialysis (HD) and ten controls were treated with capsaicin 0.05% liniment on the upper back three times daily for 5 days. Study parameters to be investigated were wheal and flare reactions, itch and alloknesis (perifocal itch sensation induced by usually non-itching stimuli) after serotonin and histamine iontophoresis in treated and untreated skin. There were no significant differences in any parameter before and after HD. In both groups, itching was not significantly reduced by capsaicin compared to untreated skin. Itching, however, was significantly lower in capsaicin-pretreated patients when comparing to controls. In summary, topical capsaicin showed some antipruritic potency in HD patients in this experimental model and may therefore be considered as a co-medication in HD patients.